CORCEPT THERAPEUTICS INC Form 8-K August 12, 2005

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 9, 2005

## Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware	000-50679	77-0487658
(State or other jurisdiction	(Commission	(I.R.S. Employe
of incorporation)	File Number)	Identification No
149 Commonwealth Drive, Menlo Park, California		94025
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including	area code:	650-327-3270
275 Mid	ddlefield Rd. Suite A, Menlo Park, CA 94025	
Former name or former address, if changed since last repo		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
ſ	1	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

## Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2005 Corcept Therapeutics Incorporated issued a press release announcing its financial results for the quarter ended June 30, 2005. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated August 9, 2005

## Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

## Top of the Form

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corcept Therapeutics Incorporated

August 12, 2005 By: \( /s/Fred Kurland \)

Name: Fred Kurland Title: Chief Financial Officer

## Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

## Top of the Form

## Exhibit Index

Exhibit No.	Description
99.1	Q2 2005 Earnings Release